# GLUE catalysts: Monte Rosa Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/glue/catalysts

> Monte Rosa Therapeutics, Inc. (GLUE) has 5 upcoming catalysts. The next is the Monte Rosa Therapeutics, Inc. interim data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for GLUE?

Monte Rosa Therapeutics, Inc. (GLUE) has 5 upcoming catalysts. The next is the Monte Rosa Therapeutics, Inc. interim data readout, 2H 2027. Press release filed with the SEC (EX-99): "The study will evaluate prevention of flare recurrence following management of acute flares, with initial data expected in H2 2027." [Calendar and source filings](https://sec-api.dev/companies/glue/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-448527, https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/glue/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Monte Rosa Therapeutics, Inc. |
| Ticker | GLUE (Nasdaq) |
| SEC CIK | 1826457 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/glue |

## Cash runway

Cash $45.2M as of 2026-09-30; quarterly burn $41.0M; about 3.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-448568).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [MRT-2359 trial start](https://sec-api.dev/pdufa/mrt-2359) | GLUE |  | completed | "We received FDA clearance of our IND for MRT-2359 in September 2022 and initiated patient dosing in our ongoing Phase 1/2 clinical trial in October 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm)) |
| Q1 2025 | [MRT-2359 interim data readout](https://sec-api.dev/pdufa/mrt-2359) | GLUE | MYC-driven solid tumors and initial data | scheduled | "Building on this tremendous momentum, we enter the new year excited to disclose additional Phase 1/2 clinical data for MRT-2359 in patients with MYC-driven solid tumors and initial data from our Phase 1 single and multiple ascending dose trial of MRT-6160, both of which are anticipated in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/glue-ex99_1.htm)) |
| Q1 2025 | [MRT-6160 interim data readout](https://sec-api.dev/pdufa/mrt-6160) | GLUE |  | scheduled | "Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/glue-ex99_1.htm)) |
| March 20, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025042319/glue-ex99_1.htm)) |
| May 8, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025066370/glue-ex99_1.htm)) |
| Jul 2025 | [MRT-8102 trial start](https://sec-api.dev/pdufa/mrt-8102) | GLUE |  | completed | "In July 2025, Monte Rosa dosed the first subjects in a Phase 1 study of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/glue-ex99_1.htm)) |
| August 7, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/glue-ex99_1.htm)) |
| November 6, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/glue-ex99_1.htm)) |
| December 16, 2025 | [MRT-2359 interim data readout](https://sec-api.dev/pdufa/mrt-2359) | GLUE |  | completed, positive | "On December 16, 2025, the Company announced positive interim data from its ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic CRPC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/glue-20251216.htm)) |
| 1H 2026 | [MRT-8102 interim data readout](https://sec-api.dev/pdufa/mrt-8102) | GLUE | inflammatory diseases driven | scheduled | "Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 inflammasome; initial readout including data from high-CVD risk cohort on track for H1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/glue-ex99_1.htm)) |
| 2026 | [MRT-6160 trial start](https://sec-api.dev/pdufa/mrt-6160) | GLUE |  | scheduled | "Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of the VAV1-directed MGD MRT-6160 (DDY391) in immune-mediated diseases in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm)) |
| 2026 | [MRT-2359 trial start](https://sec-api.dev/pdufa/mrt-2359) | GLUE |  | scheduled | "The Company plans to initiate a Phase 2 study (MODeFIRe-1) in 2026 of up to 25 patients to efficiently assess the efficacy of MRT-2359 in combination with the second-generation AR inhibitor apalutamide in mCRPC patients with AR mutations, with potential to expand the study into additional patient subsets." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-ex99_1.htm)) |
| January 7, 2026 | [MRT-8102 interim data readout](https://sec-api.dev/pdufa/mrt-8102) | GLUE |  | completed, positive | "On January 7, 2026, the Company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/glue-20260107.htm)) |
| March 17, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-ex99_1.htm)) |
| May 7, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-ex99_1.htm)) |
| 2H 2026 | [MRT-8102 topline data readout](https://sec-api.dev/pdufa/mrt-8102) | GLUE | elevated CVD risk | scheduled | "Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-ex99_1.htm)) |
| 2H 2026 | [ASCVD (ascvd) topline data readout](https://sec-api.dev/pdufa/ascvd) | GLUE |  | scheduled | "The GFORCE-1 study explored multiple dose levels in a 4-week treatment regimen and 4 weeks of safety follow-up to accelerate dose selection and development in multiple indications, including in atherosclerotic cardiovascular disease (ASCVD), gout, and hidradenitis suppurativa, with an anticipated readout in H2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm)) |
| August 6, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm)) |
| September 8, 2026 | [MRT-6160 trial start](https://sec-api.dev/pdufa/mrt-6160) | GLUE | Sjögren's disease | completed | "BOSTON, Mass., September 8, 2026 - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with Sjögren's disease (SjD), the second most prevalent rheumatic autoimmune disease1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-ex99_1.htm)) |
| Oct 2026 | [MRT-8102 topline data readout](https://sec-api.dev/pdufa/mrt-8102) | GLUE |  | completed, positive | "In October 2026, we announced positive topline results from GFORCE-1, our completed Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk, and currently expect to initiate GFORCE-2, a Phase 2b study in patients with coronary artery disease, in the first half of 2027, as well as GEMINI-1, a Phase 2 study in patients with gout, in the fourth quarter of 2026 or first quarter of 2027, and GALAXY-1, a Phase 2 study in patients with moderate to severe hidradenitis suppurativa, in the first half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448568/glue-20260930.htm)) |
| Q4 2026 | [MRT-8102 trial start](https://sec-api.dev/pdufa/mrt-8102) | GLUE | gout flares, GFORCE-3, in Q4 2026 or Q1 2027 | scheduled | "Initiation of Phase 2 study of MRT-8102 in gout expected in Q4 2026, with data update expected in H2 2027; additional Phase 2 initiation in hidradenitis suppurativa anticipated in H1 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm)) |
| November 5, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm)) |
| 2H 2027 | [Monte Rosa Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | scheduled | "The study will evaluate prevention of flare recurrence following management of acute flares, with initial data expected in H2 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm)) |
| 2H 2027 | [Monte Rosa Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | scheduled | "We expect initial data from our Phase 2 gout study in H2 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm)) |
| 2H 2027 | [MRT-8102 interim data readout](https://sec-api.dev/pdufa/mrt-8102) | GLUE |  | scheduled | "Initiate GEMINI-1 Phase 2 study of MRT-8102 in gout in Q4 2026, with initial data expected in H2 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm)) |
| October 2027 | [Oral mrt-2359 primary completion](https://sec-api.dev/pdufa/oral-mrt-2359) | GLUE |  | scheduled | "NCT07745361 (Study of Oral MRT-2359 With Apalutamide in Prostate Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Monte Rosa Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07745361)) |
| Oct 2027 to Jan 2028 | [Oral mrt-2359 topline data readout](https://sec-api.dev/pdufa/oral-mrt-2359) | GLUE |  | scheduled | "NCT07745361 (Study of Oral MRT-2359 With Apalutamide in Prostate Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Monte Rosa Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07745361)) |

## Drugs

- [ASCVD (ascvd)](https://sec-api.dev/pdufa/ascvd): 
- [MRT-2359](https://sec-api.dev/pdufa/mrt-2359): myc-driven solid tumors and initial data
- [MRT-6160](https://sec-api.dev/pdufa/mrt-6160): sjögren's disease
- [MRT-8102](https://sec-api.dev/pdufa/mrt-8102): elevated cvd risk, inflammatory conditions driven, elevated cardiovascular disease, coronary artery disease, gout flares, gforce-3, in q4 2026 or q1 2027, moderate to severe hidradenitis suppurativa in h1 2027
- [Oral mrt-2359](https://sec-api.dev/pdufa/oral-mrt-2359): Castration-Resistant Prostate Cancer (CRPC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/glue/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GLUE catalysts: Monte Rosa Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/glue/catalysts

```bibtex
@misc{secapidev_companies_glue_catalysts_20261116,
  title        = {GLUE catalysts: Monte Rosa Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/glue/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_glue_catalysts_20261116","title":"GLUE catalysts: Monte Rosa Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/glue/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
